PROCEPT BioRobotics receives FDA clearance for HYDROS robotic system
Evidence notes
- PROCEPT BioRobotics received FDA 510(k) clearance for HYDROS, its next-generation robotic system for Aquablation therapy.
- HYDROS extends the company''s urology robotics platform with image-guided planning and treatment workflow updates.
- The regulatory milestone is a core commercial proof point for PROCEPT''s surgical robotics profile.
Company context
PROCEPT BioRobotics develops surgical robotic systems for Aquablation therapy, including image-guided robotic waterjet treatment for benign prostatic hyperplasia.